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Objective: Extracellular inorganic pyrophosphate (ePPi) plays a key role in the regulation of normal and
pathologic mineralization. The purpose of this work was to evaluate the role of P1 and P2 purine
receptors in modulating ePPi production by articular chondrocytes.
Methods: Porcine cartilage explants and chondrocyte monolayers were cultured in the presence of P1
agonists, or a P2 agonist or antagonist and inhibitors of P2 signaling. Ambient media ePPi concentrations
were measured after 48e96 h.
Results: The P1 agonists NECA and CGS 21680 signiﬁcantly decreased ePPi concentrations surrounding
chondrocytes and cartilage explants. The P2 agonist, ADP, increased ePPi levels, and the P2 antagonist,
suramin, decreased ePPi concentrations. Thapsigargin and 1,2 bis-(2-aminophenoxy)ethane-N,N,N0N0-
tetra acetic acid (BAPTA), which dampen Ca2þ-related P2 signaling, suppressed the response to ADP.
Conclusions: Purine receptors are important regulators of ePPi production by chondrocytes. P1 receptor
stimulation diminishes and P2 receptor stimulation enhances ePPi production. Alterations in receptor
signaling or aberrations of extracellular purine nucleotide metabolism resulting in abnormal quantities
or proportions of P1 and P2 receptor ligands could foster changes in ePPi production that in turn affect
mineralization. We propose a homeostatic role for extracellular purine nucleotides and purine receptors
in stabilizing ePPi concentrations.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Physiologic and pathologic mineralization are highly regulated
processes. Among other factors, homeostatic mechanisms main-
taining physiologic extracellular inorganic pyrophosphate (ePPi)
concentrationsare crucial in regulatingmineralization.At physiologic
levels, ePPi inhibits ectopic deposition of hydroxyapatite-like basic
calcium phosphate (BCP) mineral. Animal models of diminished ePPi
generation exhibit pathologic BCP deposits in vascular and peri-
articular structures that do not normally mineralize1. Such models
include: themouse progressive ankylosismodel, inwhich amutation
in the ank gene, results in a truncated and dysfunctional form of
progressive ankylosis (ANK) protein, a putative intracellular to
extracellular PPi transporter, thus leading to decreased ePPi levels
and BCP deposition2; tiptoe walking (ttw)3 and plasma cell glyco-
protein-1, ectonucleotide pyrophosphatase-1 (PC-1, ENNP-1)
knockoutmice4 inwhichdeﬁcient activityof PC-1, anePPi-generatingts to: Ann K. Rosenthal,
al Center, 5000 W. National
Tel: 1-414-384-2000x41913;
.
s Research Society International. Pectoenzyme, results in similarly distributed ectopic BCP calciﬁcation;
and “idiopathic” infantile arterial calciﬁcation, the human counter-
part of PC-1 deﬁciency inwhich children develop extensive vascular
calciﬁcation and calciﬁc periarthritis5,6.
On the other hand, excess ePPi predisposes to calcium pyro-
phosphate dihydrate (CPPD) crystal deposition in articular cartilage
and interferes with normal BCP mineralization of bone. Elevated
synovial ﬂuid ePPi concentrations occur in most patients affected
with CPPD crystal deposition disease7,8. Elevated plasma and urine
ePPi levels occur in hypophosphatasia9, a condition characterized
by low alkaline phosphatase activity. In hypophosphatasia, excess
systemic ePPi concentrations promote CPPD crystal formation in
cartilage and hinder normal apatite formation in bone. The latter
effect may be explained by PPi adsorbed to BCP thereby acting as
a BCP crystal growth poison10. Thus, both increased and decreased
ePPi levels lead to disease states.
Concentrations of ePPi in biologic ﬂuids are tightly regulated.
Normal plasma levels of ePPi ranged from 0.6 to 3.8 mM (95%
conﬁdence limits)8. Synovial ﬂuids from normal knees of 50 indi-
viduals contained 10 0.5 mM ePPi11. The narrow physiologic range
of ePPi in biologic ﬂuid implies homeostatic mechanisms, but such
mechanisms remain poorly understood.ublished by Elsevier Ltd. All rights reserved.
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physiologic concentrations, and promotes CPPD crystal formation
at elevated levels, is undoubtedly the chondrocyte. Articular carti-
lage chondrocytes are uniquely able to spontaneously elaborate
signiﬁcant amounts of ePPi12,13. The process of chondrocyte ePPi
elaboration is highly bioregulable in response to a number of
growth factors and cytokines14. Periarticular tissues, including
tendon and ligament, generate lesser amounts of ePPi15. Hypo-
thetically, ePPi production prevents osseous BCP mineralization
from extending into adjacent cartilage, ligament, and tendon, thus
preserving the biomechanical properties necessary for the func-
tions of these tissues.
Extracellular ATP (eATP) has historically been considered a major
precursor of ePPi14. Chondrocytes release eATP16,17 through
unknown mechanisms. eATP can be degraded by ectoenzymes with
nucleoside triphosphate pyrophosphohydrolase (NTPPPH) activity,
such as PC-1, to generate extracellular adenosine monophosphate
(eAMP) and ePPi. eAMP is further degraded to extracellular adeno-
sine by 50 nucleotidase, an ectoenzyme present on chondrocyte
membranes18. While this process generates phosphates and pyro-
phosphates that directly participate in mineral formation, recent
work suggests that eATP and its metabolites also regulate chon-
drocyte metabolism by signaling through purinergic receptors19e21,
and there are important precedents for participation of purinergic
signaling pathways in biomineralization in tissues such as bone22e24.
The purinergic receptor system is a complex network of receptors
thatvary in their ligandafﬁnityandcellulareffects25. TheP1 receptors
include four subtypes of G protein coupled receptors including A1,
A2a, A2b and A3. Adenosine and adenosine monophosphate (AMP)
are their primary natural ligands. P1 activation increases activity of
adenylate cyclase26, an enzyme activity that suppresses ePPi levels
outside chondrocytes27. P2 receptors comprise P2X receptors of
which there are seven subtypes and P2Y receptors ofwhich there are
eight subtypes.Natural agonists for P2 receptors includeATPandADP.
While P2X receptors act as ATP-gated ion channels that quickly
increase intracellular [Ca2þ], P2Y receptor activation results in
a slower rise in intracellular [Ca2þ] mediated by G proteins. Normal
chondrocytes express both P1 and P2 receptors19,21,28e30, and
respond to P2 activation by increasing intracellular [Ca2þ]31,32.
In these studies, we sought to determine whether activation of
purinergic receptors on articular chondrocytes alters ePPi accu-
mulation in chondrocytes and cartilage. We report here that
stimulation of chondrocyte P1 receptors decreases and P2 receptor
stimulation increases ePPi elaboration by articular chondrocytes.
Methods
Materials
Dulbecco’s modiﬁed Eagle’s Medium (DMEM) and fetal bovine
serum (FBS) were from Mediatech, Inc. (Herndon, VA).
PeneStrepeFungizone (PSF) and N-(2-hydroxyethyl)piperazine
(2-ethane sulphonic acid) (HEPES) buffer were purchased from
Grand Island Biological (GIBCO/Invitrogen, Carlsbad CA). All other
compounds were from SigmaeAldrich Chemical Co., (St. Louis, MO)
unless otherwise speciﬁed.
Cartilage explant cultures
Hyaline articular cartilage was obtained from the distal femurs
of freshly slaughtered 3e5 year old, 300e500 lb, adult pigs from
a local packing plant (Johnsonville Foods, Inc., Watertown, WI). The
superﬁcial cartilage was removed and minced into pieces approx-
imately 5 mg inweight and incubated overnight in DMEMwith 10%
FBS and 1% PSF (DMEM-1) at 37C in a 5% CO2 atmosphere. Mediawere changed the next day and explants cultures were performed
in a 20-fold (vol/wet wt) volume of DMEM buffered with 25 mM
HEPES to pH 7.4, 0.5% heat inactivated FBS and 1% PSF (DMEM-2)
with or without additional reagents to be tested. Cultures were
performed for 48e96 h, a time frame corresponding to the recog-
nized peak of ePPi accumulation12.
Chondrocyte monolayer cultures
Chondrocytes were isolated from cartilage by sequential enzy-
matic digestion as described previously33. Cells were plated as high
density (4.5105 cells/cm2) monolayers in DMEM-1 and were
used solely as primary cultures, so as to preserve the differentiated
chondrocyte phenotype. Cell cultures were used within 1 week of
plating. DMEM-1 was removed and changed to DMEM-2 24 h
before the initiation of an experiment.
Purine receptor activation and inhibition, and inhibition of
calcium ﬂuxes
P1 purine receptor agonists including 10 mM NECA (50(N-ethy-
carboxamido)adenosine), 300 mM CGS 21680, and 100 mM adeno-
sine were added directly to chondrocytes or cartilage explants at
the onset of each experiment. Concentrations chosen were those
demonstrated to be maximally active in prior studies. ADP (20 mM)
was used as a P2 agonist. In order to dampen P2 signaling, cartilage
and chondrocytes were ﬁrst treated with BAPTA (1,2 bis-(2-ami-
nophenoxy)ethane-N,N,N0,N0-tetra acetic acid) or thapsigargin
before the addition of ADP. Cells were loaded with BAPTA by
removal of DMEM-1 and replacement with phosphate buffered
saline (PBS) containing 10 mM BAPTA for 2 h. Loading medium was
removed and cells were washed with DMEM-2, then incubated in
DMEM-2 with or without ADP. Under these conditions, chon-
drocyte cytosolic [Ca2þ] is maintained at normal resting levels34.
Similarly, cytosolic [Ca2þ] was stabilized in some chondrocyte
cultures by adding 1.5 mM thapsigargin dissolved in dimethyl sulf-
oxide (DMSO) to DMEM-2 1 h before the addition of agonists.
Control wells for thapsigargin experiments received an identical
amount of DMSO without thapsigargin. ePPi measurements were
performed between 48 and 96 h of incubation.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA from chondrocytes was isolated by the acidiﬁed
guanidinium isothiocyanate method, using TRIzol reagent (Life
Technologies, Grand Island, NY). One microgram of total RNA was
reverse transcribed into complementary DNA in the presence of
50 pM oligo (DT12e18), primer (Life Technologies), 10 units of
RNAse inhibitor (Amersham, Piscataway, NJ), 10 RT buffer,
deoxyribonucleotide triphosphate (dNTP) mix (5 mM each dNTP)
and Omniscript reverse transcriptase (Omniscript RT kit, Qiagen
Inc, Valencia, CA) for 60 min at 37C. Ampliﬁcation of generated
cDNA was performed in a GeneAmp PCR System 2400 thermo-
cycler (PerkineElmer Biosystems, Foster City, CA) using a PLATI-
NUMPCR SUPERMIX (Life Technologies). The gene speciﬁc
primer pairs were as follows: for P1 (adenosine) receptors (A1, A2a,
A2b, A3): for A121, sense 50-CTCGCCATCCTCATCAACATT-30 and
antisense 50-CAGCCAAACATAGGGGTCAGTC-30; for A2a27, sense
50-GCCCCTCTCTGGCTCATGTACCTG-30 and antisense 50-TCATCAG-
GACACTCCTGCTCCATC-30; for A2b28, sense 50-GAGCTGATGGAC-
CACTCGAGG-30 and antisense 50-ACACGAGAGCAGGCTGTACC-30;
for A327, sense 50-AACGTGCTGGTCATCTGCGTGGTC-30 and anti-
sense 50-GTAGTCATTCTCATGACGGAAAC-30; and for P2 receptors
(P2Y1 and P2Y2)35: for P2Y1, sense 50-TGTGGTGTACCCCCT-
CAAGTCCC-30 andantisense50-ATCCGTAACAGCCCAGAATCAGCA-30;
Fig. 1. RT-PCR of P1 and P2 receptors in primary articular chondrocytes. Total RNA was
isolated from porcine articular chondrocytes and subjected to RT-PCR for four subtypes
of P1 receptors and two subtypes of P2Y receptors. Bands corresponding to the mRNA
for these receptors are shown. mRNA for GAPDH was used as a control for gel loading.
Appropriate size bands were seen for A1, A2a, A2b, P2Y1 and P2Y2 purinergic
receptors.
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Fig. 2. The effects of P2 agonists and antagonists on ePPi elaboration. Chondrocytes
monolayers (grey bars) or cartilage explants (white bars) were incubated with no
additives (control) or the P2 agonist 20 mM ADP with and without the P2 antagonist,
20 mM suramin. ePPi levels were measured after 72 h in chondrocytes and 48 h in
organ cultures. Values are expressed as means CI (N¼ 6). ADP signiﬁcantly increased
ePPi levels while suramin signiﬁcantly decreased ePPi levels.
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50-CATGTTGATGGCGTTGAGGGTGTG-30; and for a house-keeping
gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH)36,
sense 50-GGTGAAGGTCGGAGTCAACG-30 and antisense 50-CAAAG-
TTGTCATGGATGACC-30. Cycling parameters were as follows: for A1,
A2a and A3, [95C for 30 s, 54C for 30 s, 72C for 30 s] 45 cycles;
for A2b, [95C for 30 s, 56C for 30 s, 72C for 30 s] 45 cycles; for
P2Y1 and P2Y2, [95C for 30 s, 58C for 30 s, 72C for 30 s] 40
cycles; and for GAPDH, [95C for 30 s, 55C for 30 s, 72C for 30 s]
25 cycles. An additional elongation step at 72C for 7 min was
included. Transcripts were analyzed in 1.2% agarose/TAE gel elec-
trophoresis and visualized by SYBRGREEN-I (Sigma, St. Louis,MO)
using image scanner Storm (Molecular Dynamics, Sunnyvale, CA).
The expected transcript sizes were 245 bp for A1, 450 bp for A2a,
341 bp for A2b, 441 bp for A3, 259 bp for P2Y1, 362 bp for P2Y2, and
496 bp for GAPDH, respectively. Each PCR productwas isolated from
the agarose gel and the sequence was conﬁrmed by dideoxy chain-
termination sequencing after subcloning PCR product into TOPO
TA cloning vector (Invitrogen).
Measurement of ePPi and cyclic adenosine monophosphate
(cAMP) levels
The ePPi assay was performed in conditioned media by the 14C
labeled uridine 50 diphosphoglucose (UDPG) method as previously
described37. Brieﬂy, this assay is based on the conversion of 14C
UDPG to 14C glucose-1 phosphate and uridine triphosphate in the
presence of PPi. Charcoal is then used to separate reacted from un-
reacted product, and counts in the supernatant directly correlate
with concentrations of PPi. cAMP was assayed using a commercial
kit (Assay Designs, Ann Arbor, MI). Cells grown in 24-well plates
were treated with NECA or vehicle in DMEM-2, and after 30 min or
4 h, media were removed and the cell layers were treated with
0.1 M HCl. Forskolin was used as a positive control. The cell lysates
were removed from the wells, and centrifuged to remove debris.
The supernatant was used directly in the assay according to the
manufacturer’s directions.
Statistical analysis
A one-way analysis of variance (ANOVA) with Dunnett’s post-
test was used to compare differences between groups. Only
differences with P values <0.05 were considered statistically
signiﬁcant. All results are presented as means 95% conﬁdence
intervals (CI). Experiments were repeated 3e5 times, using cells
and tissues from different animals with each experiment. Each
experimental group contained six replicates.
Results
Articular chondrocytes express P1 and P2 receptor mRNA
To conﬁrm prior work characterizing P1 and P2 receptors in
articular chondrocytes19,21,29, we performed RT-PCR for the best
characterized P1 and P2 receptor subtypes (Fig. 1). RT-PCR revealed
abundant message for the P1 receptors A1 and A2b and the P2
receptors Y1 and Y2. Weaker signals were observed for the A2a
receptor and no message was detected for the A3 receptor.
P1 agonists decrease ePPi accumulation in cartilage and
chondrocytes
The potent P1 agonist, NECA, signiﬁcantly decreased accumu-
lation of ePPi around cartilage explants. ePPi levels were
29.210.3 mM in control cultures and 15.9 4.7 mM with 10 mMNECA. Another P1 agonist, CGS 21680, also signiﬁcantly decreased
ePPi accumulation in cartilage conditioned media to 9.12.9 mM
ePPi. In chondrocyte monolayer cultures, NECA diminished ePPi
concentrations signiﬁcantly, but less dramatically than in explants
(13.31.5 mM in controls vs 11.0 0.9 mM in NECA treated
cultures). Adenosine, a natural P1 agonist, did not signiﬁcantly
affect ePPi accumulation in cartilage conditioned media. ePPi levels
in the control cultures were 12.5 2.0 mM and were 13.8 1.7 mM
in adenosine-treated cultures. However, when dipyridamole and
adenosine were added simultaneously, ePPi elaboration was
signiﬁcantly decreased to 5.21.0 mM ePPi. Dipyridamole prolongs
the effect of adenosine on P1 receptors, likely by retarding inter-
nalization of adenosine38. Using forskolin as a positive control,
stimulation of monolayer chondrocytes with the P1 agonist NECA
was accompanied by signiﬁcantly elevated levels of intracellular
cAMP, a known inhibitory signal for ePPi elaboration (control
3.6 2.7 mM, forskolin 41.918.9 mM, NECA 5.9 0.5 mM).
P2 agonists increase ePPi accumulation in cartilage and
chondrocytes in a calcium-dependent manner (Fig. 2)
Addition of the P2 agonist ADP to chondrocyte cultures signiﬁ-
cantly increased media ePPi accumulation. Cartilage explants
cultured in the presence of ADP also exhibited signiﬁcantly more
ePPi elaboration. The P2 antagonist, suramin, signiﬁcantly
decreased both basal and ADP-stimulated production of ePPi by
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with suramin in the presence of ADP, similar decreases in ePPi
accumulation were seen.
P2Y signaling involves calcium-mobilizing G proteins. Thapsi-
gargin and BAPTA inhibit the ﬂuctuations in cytosolic calcium
concentrations induced by P2Y-linked G proteins34. Thapsigargin,
which inhibits the release of endoplasmic reticular calcium,
signiﬁcantly decreased basal and slightly diminished ADP-stimu-
lated ePPi elaboration by chondrocyte monolayers and cartilage
explants (Fig. 3). The intracellular calcium chelator, BAPTA, also
dampens cytosolic calcium ﬂuxes. BAPTA signiﬁcantly diminished
ePPi accumulation around chondrocytes after 48 h of incubation
(Fig. 3). In cartilage explants, BAPTA also signiﬁcantly suppressed
ePPi accumulation in the presence or absence of ADP (Fig. 3).
Discussion
ePPi elaboration is a highly regulated process with important
ramiﬁcations for both pathologic and physiologic mineralization in
multiple tissues. Stimuli for articular chondrocyte ePPi formation
include transforming growth factor b, bone morphogenic proteins,
ascorbate and transglutaminases. Inhibitors include insulin-like
growth factor-1, interleukin-1, and probenecid14. Tight regulation
of ePPi levels prevents the serious sequellae of abnormal ePPi
accumulation, including underproduction of ePPi, which can result
in ectopic BCP crystal deposition and overproduction of ePPi, which
causes CPPD crystal formation in articular cartilage.
The current study was based upon observations that purinergic
receptor ligands are plentiful in extracellular ﬂuids surrounding
chondrocytes, and that while purinergic receptors are expressed on
chondrocytes, little is known about their actions. We report here
that P1 receptor activation diminishes chondrocyte ePPi formation
and P2 activation stimulates ePPi elaboration. A2a and A2b
subtypes of P1 receptors are present on articular chondrocytes and
signal through stimulation of adenylate cyclase, a recognized
inhibitor of ePPi accumulation. Activation of P1 receptors would be
expected to decrease ePPi formation. Consistent with this expec-
tation, we noted decreased ePPi elaboration in the presence of the
non-speciﬁc P1 agonist, NECA, which simultaneously increased
intracellular cAMP levels. Similar effects were observed with the P1
agonist CGS 21680, thought to be more speciﬁc for the A2a receptor
subtype. The physiologic P1 agonist adenosine did not inﬂuence
ePPi elaborationwhen added alone, but decreased ePPi elaboration0
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Fig. 3. The effect of intracellular calcium level ﬁxation on ePPi elaboration. Chondrocyte
monolayers (grey bars) or cartilage explants (white bars) were exposed to no additives,
1.5 mM thapsigargin (Thaps) or 10 mM BAPTA for 2 h. Media were removed, and chon-
drocytes and cartilage explants were cultured with no additives (control) or with 20 mM
ADP for 48 h. ePPi levels were measured and are expressed as means CI (N¼ 6). Both
thapsigargin and BAPTA signiﬁcantly decreased both basal and ADP-stimulated PPi
levels.when added along with dipyridamole, which blocks entry of
adenosine into cells and hence increases its extracellular half life. In
contrast, P2 receptor agonists, such as ADP, increased PPi produc-
tion, and suramin, a P2 receptor antagonist, suppressed this
increase. If intracellular [Ca2þ] are ﬁxed and unchangeable, ADP has
little effect, suggesting a role for [Ca2þ] ﬂuxes in P2 signaling.
The source of eATP that reaches the chondrocyte surface is
conjectural. Joint ﬂuid in equilibrium with cartilage extracellular
matrix contains ATP levels of 50e200 nM39. Potential sources of
synovialﬂuidATP include chondrocytes, subchondral bone, synovial
ﬂuid cells and synovium. Release of eATP by chondrocytes has been
described in chondron cultures after mechanical stimulation and
released ATP may function as an autocoid stimulant17. While the
mechanism of ATP release by chondrocytes is not known, some
evidence suggests that hemichannels, such as connexin 43 may be
involved30. Inothernon-articular tissues, pannexinhemichannels40,
cystic ﬁbrosis transmembrane conductance regulator (CFTR) gene
product41, maxianion channels42, and vesicular release43 have been
implicated in cellular ATP release. Cells in synovial ﬂuidmay release
ATP during cell death or after injury. Of particular note are synovial
erythrocytes that release ATP in a variety of situations44,45. Inter-
estingly, synovial ﬂuids from patients with CPPD deposition disease
often exhibit blood-tinged joint ﬂuids46.
The purpose of eATP in cartilage is also poorly understood. ATP
may act as a mechanotransducer in cartilage20,47, and changes in
purinergic receptors in osteoarthritic chondrocytes may alter this
response48. This role may be particularly relevant for chondrocytes
within cartilage that lack gap junction-mediated intercellular
communication mechanisms. ATP is also an important mediator of
pain49, and can affect anabolic and catabolic processes in
chondrocytes20,21.
The metabolism of eATP and the interactions of eATP metabo-
lites with purinergic receptors on chondrocytes may represent
a homeostatic mechanism for biomineralization (Fig. 4). Degrada-
tion of eATP by ecto-NTPPPH generates ePPi and eAMP, and
degradation by ATPase produces extracellular adenosine diphos-
phate (eADP) and ePi. When NTPPPH is the predominantly active
cartilage ectoenzyme, ePPi is generated from eATP. eAMP produced
as a catalytic co-product diminishes chondrocyte ePPi extrusion by
its effects on P1 receptors. When ATPase is the predominant
chondrocyte ectoenzyme, lesser amounts of ePPi are produced, but
a catalytic co-product, eADP enhances chondrocyte ePPi extrusion
by interacting with P2 receptors. This complex system could
dampen ﬂuctuations of ePPi levels and perhaps explain the
remarkably narrow range of ePPi levels in normal biologic ﬂuids.
These studies are not without limitations. Synthetic agonists and
antagonists can have non-speciﬁc effects, while natural ligands can
bequicklymetabolizedbyectoenzymesor internalizedbymembrane
transporters. Future studies with more speciﬁc agonists and antag-
onists may be warranted. As calcium signaling can be initiated by
agonists of both P2X and P2Y receptors, and we did not speciﬁcally
look for P2X receptormRNA in chondrocytes, we cannot conclusively
implicate one class of P2 receptor subtype in the P2 effect.Fig. 4. Hypothetical scheme of ePPi homeostasis maintained by interaction of the ATP
hydrolysis products of ecto-ATPase and ecto-NTPPPH acting on purinergic receptors.
A.K. Rosenthal et al. / Osteoarthritis and Cartilage 18 (2010) 1496e15011500In summary, we show here that while eATP and its extracellular
metabolites may directly participate inmineral formation, they also
affect chondrocyte ePPi production at a cellular level by signaling
though purinergic receptors. Future studies to determine the rela-
tive importance of these effects and the source of eATP in cartilage
are warranted.Contributions
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